Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019829 (
Hodgkin's disease
)
30,247
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A 70-year-old woman with a 2-year history of B-cell chronic lymphocytic leukemia (CLL) developed
headache
, fever, chills, and weakness. Bone marrow examination revealed both CLL and large cell immunoblastic lymphoma (Richter's syndrome). As expected, the CLL was of B-cell lineage. The neoplasm expressed low-density monotypic IgM lambda, the pan-B-cell antigens CD19, CD20, and CDw75, and the CD5 and CD43 antigens. The large cell immunoblastic lymphoma was of T-cell lineage, positive for the CD45RB, CD3, CD45RO, and CD43 antigens, and negative for the CD20 and CDw75 antigens. Both neoplastic components were negative for Epstein-Barr virus RNA and latent membrane protein. Although 3% to 5% of patients with B-cell CLL may develop higher-grade lymphoma, usually the lymphoma is of B-cell lineage and often represents a histologic manifestation of clonal evolution. Less commonly, B-CLL patients may develop transformation to a higher grade tumor that resembles
Hodgkin's disease
. Both the usual form of Richter's syndrome and particularly the
Hodgkin
's variant of Richter's syndrome may be associated with Epstein-Barr virus. Patients with B-cell CLL rarely develop a higher grade lymphoma of T-cell lineage. To our knowledge, only one other example has been reported in the literature. Epstein-Barr virus was not associated with either neoplasm in this case.
...
PMID:B-cell chronic lymphocytic leukemia followed by high grade T-cell lymphoma. An unusual variant of Richter's syndrome. 787 59
The objective of this phase-I study was to establish the maximum tolerable dose of recombinant human interleukin-3 (rhIL-3) after salvage chemotherapy in patients with malignant lymphoma. Twenty-one patients with relapsed
Hodgkin's disease
or intermediate/high-grade non-Hodgkin's lymphoma received rhIL-3 after the second cycle of DHAP chemotherapy (cisplatin, cytosine-arabinoside, dexamethasone). Cycles 1 and 3 were given without rhIL-3. The rhIL-3 was administered as a continuous intravenous infusion for 10 days starting 48 h after chemotherapy in cycle 2. Five different dose levels of rhIL-3 (0.25, 1.0, 2.5, 5.0, and 10.0 micrograms/kg/day) were sequentially tested. At the three lowest dose levels one double-blinded placebo was included for every four patients per dose level. Low-grade fever occurred in 15/21 patients, unrelated to the dose of rhIL-3. Nausea and vomiting (grade 1-2) occurred in seven patients.
Headache
was dose related, with 3/4 patients at a dose of 10 micrograms/kg/day experiencing troublesome grade-2
headache
precluding further dose escalation. Facial flushing developed in 3/8 patients at the highest dose levels of rhIL-3. There was a significant increase in eosinophil count during rhIL-3 (p = 0.03 cycle 2 vs cycle 1 and p = 0.002 cycle 2 vs cycle 3) without accompanying clinical signs of symptoms. No increase in basophil count was observed. There were no increased plasma levels of interleukin-6 or macrophage colony-stimulating factor (M-CSF) during rhIL-3. We conclude that rhIL-3 can be safely administered as a continuous intravenous infusion for 10 days after DHAP chemotherapy. Dose-limiting side effects, especially
headache
, occur at a dose of 10 micrograms/kg/day.
...
PMID:The tolerability of continuous intravenous infusion of interleukin-3 after DHAP chemotherapy in patients with relapsed malignant lymphoma. A phase-I study. 821 38
We report a rare case of
Hodgkin's disease
in which intracranial involvement developed during the course of the patients illness. A 20-year-old man who had complained of lymph node swelling on the right neck was admitted to a hospital in December 1978. Lymph node biopsy revealed
Hodgkin's disease
, and he was treated by various series of chemotherapy and radiotherapy with unsatisfactory results. He was transferred to Yamanashi Medical College Hospital in June 1985. He was in a far-advanced state at the time, and palliative treatment was applied. In the middle of May 1986, he complained of
headache
, tinnitus, and sleeplessness. Vomiting and tremor were observed by the end of May 1986. Brain CT scan revealed a space occupying lesion in the right temporal region. Whole brain irradiation of 45 Gy was effective, and the lesion disappeared. However, his general condition deteriorated and he died in November 1986. Brain autopsy could not be performed.
...
PMID:A case of intracranial involvement of Hodgkin's disease. 829 Jun 98
We performed a pilot study of human recombinant IL-6 (SDZ ILs 969) in 6 patients with poor prognosis
Hodgkin's disease
following autologous bone marrow transplantation (ABMT) to determine its safety and tolerability. IL-6 was administered the day following bone marrow infusion by subcutaneous injection once daily at a dose of 1 micro/kg/day to 3 patients and 2.5 microg/kg/day to 3 patients and was continued for 6 weeks or until platelet engraftment (>50 x 10(9)/L independent of transfusion). No severe or life threatening toxicities were seen at either dose level. A reversible elevation in alkaline phosphatase occurred in 4 patients and all patients complained of
headache
, myalgias, and fever. Gastrointestinal toxicity was low, grade 3-4 mucositis occured less frequently than in similarly-treated historical controls receiving GM-CSF. Serum concentrations of other cytokines such as IL-3 and G-CSF after ABMT differed from results obtained in transplant recipients given GM-CSF. The median time to an ANC >0.5 x 10(9)/L was 25.5 days and to a platelet count of >20 x 10(9)/L independat of transfusion was 35.5 days. Engraftment was no different from controls. Five patients relapsed at a median of 5 months post-ABMT and four remain alive at a median of 12 months post-ABMT. We conclude that IL-6 administration is safe and well tolerated in patients following ABMT. Further efforts to evaluate its effect on hematopietic recovery as well as relapse following transplantation in a larger patient series are warranted.
...
PMID:A phase I study of interleukin-6 after autologous bone marrow transplantation for patients with poor prognosis Hodgkin's disease. 925 Aug 27
Dural sinus thrombosis (DST) has been reported in association with cancer in both adults and children. We describe the seven patients seen with this complication in our centre between 1981 and 1995. Diagnosis was confirmed by either cerebral CT scanning, MRI or angiography. Median age was 13 years (range 8-15). Six patients were boys. Six children were being treated for non-
Hodgkin lymphoma
and one for neuroblastoma. Presenting symptoms were seizures and transient neurologic deficit, often preceded by
headaches
. The probable cause of DST was found in two cases. Tumour localisation in the central nervous system (CNS) probably caused DST in one patient who was treated for ki 1 lymphoma. Dehydration in combination with a poor general condition seemed to be the cause of DST in the patient with neuroblastoma. In five children with stage III or IV non-
Hodgkin lymphoma
(three lymphoblastic lymphoma; two Burkitt's lymphoma), etiology remained unknown. In these children, DST occurred early in the course of therapy. The median interval between start of chemotherapy and onset of symptoms was 19 days (range 8-40). No child had received L-asparaginase. Prognosis was favourable, with symptoms completely disappearing without therapy within 1 to 5 days. The incidence of DST in patients with advanced stage non-
Hodgkin lymphoma
during induction and consolidation was calculated to be below 3%. We conclude that DST is rarely diagnosed in children with cancer. Occurrence during the initial phase of therapy for non-
Hodgkin lymphoma
is associated with a benign prognosis.
...
PMID:Dural sinus thrombosis in children with cancer. 1211 89
A 71-year-old man developed general fatigue, appetite loss, and
headache
. Two months later, he noticed diplopia. Examination demonstrated reduced visual acuity and complete ophthalmoplegia of the left eye. Brain MRI disclosed a mass that extended from bilateral cavernous sinus to the clivus. There were left cervical lymphadenopathy and a right abdominal mass. A needle biopsy of the abdominal mass revealed non-
Hodgkin lymphoma
. Although malignant lymphoma at the cavernous sinus is not common, it should be an important consideration in the differential diagnosis of mass at the cavernous sinus.
...
PMID:[Malignant lymphoma at the cavernous sinus]. 1072 58
A case with systemic non-
Hodgkin lymphoma
involving the sella turcica and kidney is reported. A 69-year-old man presented with a progressive two month history of visual disturbance and
headache
. Neurological examination revealed bilateral visual disturbance and right optic atrophy. MRI showed a contrast-enhancing mass in the sella turcica. The tumor extended to the right optic nerve. Without extensive studies for systemic disease, the patient immediately underwent transsphenoidal surgery. The slightly firm, fibrous and vascular-rich tumor was subtotally removed. The histopathological examination revealed a malignant lymphoma, diffuse-large-cell type with B-cell phenotype. The postoperative course was uneventful and the patient's symptoms subsided gradually. The patient received radiation therapy and the tumor disappeared. Postoperative CT examinations of the abdomen and pelvis revealed a large mass at the upper portion of the left kidney. Ga-scan also suggested the mass to be consistent with the abdominal CT. However, the patient suddenly died of acute heart failure with unknown cause just before starting chemotherapy for systemic lymphoma. Patients presenting primary central nervous system lymphoma (PCNSL) may have systemic non-
Hodgkin lymphoma
. To exclude systemic non-
Hodgkin lymphoma
, systemic investigation is essential for the initial management of patients presenting PCNSL.
...
PMID:[Systemic non-Hodgkin lymphoma initially presented with visual disturbance due to intrasellar lymphoma--a case report]. 1121 68
We describe 4 cases of non-Hodkin's lymphomas that were interesting because of their curiosal clinical courses and spontaneous complete remissions during the course of high malignancy lymphoma. We present three of them for the first time in Poland. Case 1: a 61-year old woman was admitted to the hospital because of the
headache
, lasting for 4 months before hospitalization and right hemiparesis. CT scans revealed the presence of tumor in the temporo-occipital region. The diagnosis of B-cell lymphoma was established at histopathological examination of the postoperative material. Co60--therapy of these region was applied after the operation with good response. Case 2: a 38-year woman was admitted to the hospital because of L5-S1 spondylolisthesis to operate it. During the hospitalization haemolytic anaemia of unknown origin, thrombocytopoenia, splenomegaly, fever and rising acute insufficiency of kidneys, heart, liver and CNS were occurred. The patient died, despite applying corticosteroidotherapy. The diagnosis of intravascular lymphoma was established at postmortem examination. Case 3: a 51-year old woman was admitted to the hospital with diagnosis: anaplastic non-
Hodgkin lymphoma
B-cell type high malignancy established after the double histopathological examination of lymph nodes and biopsy of the lung. At the admission to the Department of Haematology we stated absolute regression of these changes. The patient had been only observed in the Outpatient Department over 1 year. She died after 6 months since the beginning of the relapse despite intensive chemotherapy. Case 4: a 43-year old man was admitted to the hospital because of great hyperleukocytosis, hepatosplenomegaly and neurological symptoms. The diagnosis: chronic prolymphocytic leukaemia was established. The cerebrospinal fluid examination showed presence of mononuclears which infiltrated CNS. CT scans of the brain revealed leucaemic infiltrations of the hemispheres and cerebellum. The patient died despite intensive therapy due to rising progressive multiorgan failure.
...
PMID:[Unusual cases of non-Hodgkin's lymphomas--case reports]. 1123 49
A 64-year-old man presented to his general practitioner with an history of
headaches
and recent diplopia. Neuroradiological investigation showed a sphenoid sinus mass involving the sella and the clivus. Diagnosis of non-
Hodgkin lymphoma
was made via a transsphenoidal approach. The patient subsequently underwent a 6-month course of chemotherapy (M COPPA protocol) followed by 50 Gy locoregional radiotherapy. At three years follow-up the patient was in complete clinical and radiological remission. This case underscores the importance of thorough radiological work-up for accurate identification of tumor masses involving the pituitary fossa and provides an opportunity to review the literature on the management of this rare entity.
...
PMID:[Sphenoid sinus lymphoma. Case report and review of the literature]. 1259 9
A 46-year-old man had a
headache
and a slight superior bitemporal contraction of the visual field with no lymphadenopathy. Magnetic resonance imaging showed a sellar mass and a tumor of the nasopharynx. After the nasopharyngeal tumor was resected, the patient was diagnosed as having lymphocyterich classical
Hodgkin lymphoma
at clinical stage IEA. He achieved complete remission after 3 cycles of ABVD therapy followed by involved field irradiation. After the radiotherapy, transsphenoidal resection of the pituitary tumor was performed and a diagnosis of non-functioning adenoma was established. This is the first report describing
Hodgkin lymphoma
of the nasopharynx associated with a pituitary adenoma.
...
PMID:[Hodgkin lymphoma of the nasopharynx associated with a pituitary adenoma]. 1497 34
<< Previous
1
2
3
4
5
6
7
8
9
Next >>